Capreomycin CAS:11003-38-6

Capreomycin is primarily utilized in the treatment of tuberculosis, especially when dealing with drug-resistant strains of the bacterium Mycobacterium tuberculosis. It is often part of a combination therapy regimen used to combat multidrug-resistant tuberculosis (MDR-TB) or extensively drug-resistant tuberculosis (XDR-TB) cases where traditional first-line antibiotics have failed. The administration of Capreomycin is typically via intramuscular injection and is closely monitored by healthcare professionals due to the potential for adverse effects associated with aminoglycoside antibiotics. Treatment duration and dosage are determined based on the severity of the infection, the patient's weight, renal function, and overall health status. Regular monitoring of kidney function, hearing, and potential side effects is crucial during Capreomycin therapy to ensure patient safety and treatment effectiveness. Adherence to the prescribed treatment regimen is essential to achieve optimal outcomes and reduce the risk of developing further resistance. Patients undergoing Capreomycin treatment should follow medical advice diligently and complete the full course of antibiotics to prevent treatment failure or recurrence of tuberculosis. Close collaboration with healthcare providers, along with regular check-ups and monitoring, is vital in managing tuberculosis effectively with Capreomycin while minimizing the risk of complications and promoting recovery.